Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 5;18:138. doi: 10.1186/s12885-018-4067-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Patients presenting optimal morphologic responses during treatment with regorafenib. A, B. Optimal morphologic response observed at 175 days after initiation of regrafenib. Size of tumor was slightly increased (+ 6.0%) with reduction in CT density. CEA levels were 911 ng/ml (A) and 840 ng/ml (B), respectively. C, D. Optimal morphologic response observed at 105 days after initiation of regrafenib. Size of tumor was slightly increased (+ 16.0%) with evident change in CT texture of tumor. CEA levels were 860 ng/ml (C) and 910 ng/ml (D), respectively. E, F. Optimal morphologic response observed at 90 days after initiation of regrafenib. Although there was remarkable progression of tumor in number and size, serum CEA levels decreased from 91.7 ng/ml (E) to 66.1 ng/ml (F)